Screening practices for late effects in pediatric patients on tyrosine kinase inhibitors.

被引：0
|
作者：
Smith, Stephanie M.
Sabnis, Himalee S.
Lewis, Rebecca Williamson
Effinger, Karen Elizabeth
Bergsagel, Daniel John
Patterson, Briana
Mertens, Ann C.
Sakamoto, Kathleen
Schapira, Lidia
Castellino, Sharon M.
机构：
[1] Stanford Univ, Dept Pediat, Sch Med, Div Hematol Oncol, Stanford, CA 94305 USA
[2] Childrens Healthcare Atlanta, Dept Pediat, Aflac Canc & Blood Disorders Ctr, Atlanta, GA USA
[3] Emory Univ, Atlanta, GA 30322 USA
[4] Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Atlanta, GA USA
[5] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA
[6] AFLAC Canc Ctr & Blood Disorders Svc, Atlanta, GA USA
[7] Emory Univ, Sch Med, Dept Pediat, Div Endocrinol, Atlanta, GA USA
[8] Stanford Univ, Stanford, CA 94305 USA
[9] Stanford Canc Inst, Stanford, CA USA
[10] Childrens Healthcare Atlanta, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e22527
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Tyrosine kinase inhibitors.
    He, W
    Myers, MR
    Spada, AP
    Hanney, BA
    Setzer, N
    Mailliet, P
    Gontier, S
    Guegen, JC
    Cans, P
    Orton, E
    Cheve, M
    Kubiak, GG
    Shah, HG
    O'Brien, MK
    Bilder, GE
    Allen, E
    Bissery, MC
    Page, K
    Natarajan, C
    Jayyosi, Z
    Kelley, MF
    Toutain, H
    Constan, A
    Amin, D
    Needle, S
    Galczenski, H
    Wang, W
    Perrone, MH
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U57 - U57
  • [2] Tyrosine kinase inhibitors. "-nibs"
    La Rosee, P.
    ONKOLOGE, 2011, 17 (07): : 641 - 649
  • [3] Virtual screening for kinase inhibitors.
    Lyne, PD
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U365 - U365
  • [4] Selective trkA tyrosine kinase inhibitors.
    Hudkins, RL
    Murakata, C
    Kaneko, M
    Angeles, TS
    Dionne, CA
    Neff, NT
    Vaught, JL
    Mallamo, JP
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 215 : U894 - U894
  • [5] Inhibition of calcineurin by tyrosine kinase inhibitors.
    Martin, BL
    FASEB JOURNAL, 1997, 11 (09): : A1181 - A1181
  • [6] Olanzapine for managing side effects from tyrosine-kinase inhibitors.
    Koch, Regina
    Muniz, Miguel
    Peskey, Candy
    Jatoi, Aminah
    Ruddy, Kathryn Jean
    Orme, Jacob
    Pagliaro, Lance C.
    Quevedo, Fernando
    Costello, Brian Addis
    Megan, Spychalla
    Heath, Elisabeth I.
    Zakharia, Yousef
    Singh, Parminder
    Riaz, Irbaz Bin
    Cathcart-Rake, Elizabeth Jane
    D'Andre, Stacy D.
    Loprinzi, Charles L.
    Childs, Daniel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 524 - 524
  • [7] Synthesis of PDGF receptor tyrosine kinase inhibitors.
    He, W
    Myers, MR
    Spada, AP
    Hanney, BA
    Setzer, N
    Maguire, M
    Mailliet, P
    Gontier, S
    Guegen, JC
    Cans, P
    Orton, E
    Cheve, M
    Kubiak, GG
    Shah, HC
    O'brien, MK
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U128 - U128
  • [8] Chronic myelogenous leukemic and tyrosine kinase inhibitors.
    Mahon, FX
    REVUE DE MEDECINE INTERNE, 2001, 22 (09): : 894 - 899
  • [9] QSAR study on some tyrosine kinase inhibitors.
    Kurup, A
    Garg, R
    Hansch, C
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U414 - U414
  • [10] FDA evaluation of hepatotoxicity related to tyrosine kinase inhibitors.
    Chang, J.
    Rand, M.
    Blumenthal, G. M.
    Cortazar, P.
    Kulick, C.
    Hausman, E.
    Chang, S.
    Pratt, R.
    Habtemarium, B.
    Chen, Y.
    Bullock, J.
    Orbach, R. Charlab
    Zineh, I.
    Justice, R. L.
    Pazdur, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345